Empagliflozin/Metformin (Chong Kun Dang)

恩格列净/二甲双胍 (Chong Kun Dang)

Report date: 2025/03/12 13:38:34

Base Information

Drug NameEmpagliflozin/Metformin (Chong Kun Dang)
Drug Alias NameCKD-375
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChong Kun Dang Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A